Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT
Top Page
Bolt Biotherapeutics
(NASDAQ:BOLT)
Select Model
Select Model
Rating:47Neutral
Price Target:
$5.00
▲(4.60% Upside)
Action:ReiteratedDate:04/07/26
The score is held down primarily by weak financial performance—large ongoing losses, persistent cash burn, and a weakening equity base that implies continued financing risk. Technicals are mixed but slightly supportive in the near term, while valuation offers limited upside support due to a negative P/E and no dividend.
Positive Factors
Proprietary Boltbody platform
Bolt’s Boltbody platform targets delivery of immune‑stimulating agents to the tumor microenvironment, a differentiated mechanism that can reduce systemic toxicity and improve therapeutic index. This platform-level asset creates durable competitive advantage and multiple program opportunities for licensing or co-development.
Negative Factors
High cash burn
Operating cash flow and free cash flow remain deeply negative, with cash burn closely tracking net loss. Persistent negative cash generation creates an ongoing financing requirement and raises dilution and execution risk if near‑term collaborations or financing do not materialize to cover R&D expenditures.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Boltbody platform
Bolt’s Boltbody platform targets delivery of immune‑stimulating agents to the tumor microenvironment, a differentiated mechanism that can reduce systemic toxicity and improve therapeutic index. This platform-level asset creates durable competitive advantage and multiple program opportunities for licensing or co-development.
Read all positive factors
Bolt Biotherapeutics (BOLT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.19M
Dividend YieldN/A
Average Volume (3M)29.18K
Price to Earnings (P/E)―
Beta (1Y)0.42
Revenue Growth-46.88%
EPS Growth34.83%
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.84
Shares Outstanding1,921,567
10 Day Avg. Volume31,146
30 Day Avg. Volume29,181
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.33
P/FCF Ratio-0.26
Enterprise Value/Market Cap2.19
Enterprise Value/Revenue2.61
Enterprise Value/Gross Profit3.24
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$41.00Price Target Upside757.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-19.48
Revenue Forecast (FY)$2.33M
Bolt Biotherapeutics Business Overview & Revenue Model
Company Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth facto...
How the Company Makes Money
Bolt Biotherapeutics primarily seeks to generate value and potential revenue by developing and advancing proprietary oncology drug candidates and, where applicable, partnering them with larger biopharmaceutical companies. As a clinical-stage biote...
Bolt Biotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
40
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.70M | 7.69M | 7.88M | 5.73M | 1.26M |
| Gross Profit | 6.20M | 7.69M | -53.67M | -67.39M | -74.39M |
| EBITDA | -33.14M | -66.45M | -74.34M | -88.66M | -91.59M |
| Net Income | -33.38M | -63.12M | -69.20M | -88.10M | -98.59M |
Balance Sheet | |||||
| Total Assets | 56.75M | 99.63M | 159.78M | 227.81M | 307.72M |
| Cash, Cash Equivalents and Short-Term Investments | 27.50M | 47.32M | 102.19M | 168.89M | 186.22M |
| Total Debt | 22.96M | 25.21M | 20.22M | 22.61M | 24.36M |
| Total Liabilities | 30.24M | 42.43M | 47.04M | 56.30M | 57.60M |
| Stockholders Equity | 26.50M | 57.20M | 112.74M | 171.51M | 250.12M |
Cash Flow | |||||
| Free Cash Flow | -39.92M | -61.33M | -69.73M | -78.46M | -59.40M |
| Operating Cash Flow | -39.85M | -61.29M | -69.53M | -76.50M | -57.07M |
| Investing Cash Flow | 44.30M | 57.58M | 71.04M | 57.86M | -232.20M |
| Financing Cash Flow | 19.00K | 108.00K | 253.00K | 503.00K | 311.11M |
Bolt Biotherapeutics Technical Analysis
Positive
4.78
Price Trends
4.88
Negative
5.17
Negative
5.37
Negative
Market Momentum
-0.05
Negative
53.78
Neutral
65.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLT, the sentiment is Positive. The current price of 4.78 is above the 20-day moving average (MA) of 4.41, below the 50-day MA of 4.88, and below the 200-day MA of 5.37, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 53.78 is Neutral, neither overbought nor oversold. The STOCH value of 65.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BOLT.
Bolt Biotherapeutics Risk Analysis
Bolt Biotherapeutics disclosed 64 risk factors in its most recent earnings report. Bolt Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bolt Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $7.33M | -1.38 | -60.33% | ― | 13.30% | 22.70% | |
50 Neutral | $5.61M | -25.06 | -418.83% | ― | ― | 98.58% | |
47 Neutral | $9.19M | -0.31 | -97.58% | ― | -46.88% | 34.83% | |
45 Neutral | $14.08M | -0.53 | -189.72% | ― | ― | 70.57% | |
39 Underperform | $940.69K | -1.65 | 1211.14% | ― | -59.21% | 68.97% |
* Healthcare Sector Average
BOLT
Bolt Biotherapeutics
4.78
-2.00
-29.50%
ERNA
Eterna Therapeutics
0.21
-2.77
-92.82%
XBIO
Xenetic Biosciences
3.20
0.78
32.23%
MBIO
Mustang Bio
0.74
-0.62
-45.51%
LYRA
Lyra Therapeutics
0.53
-4.18
-88.75%
INAB
IN8bio
1.43
-3.15
-68.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.